Evidence map›Paper›PMID 19167078›Full record

Trial reportOphthalmology2009

SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.

Ingrid U Scott, Paul C VanVeldhuisen, Neal L Oden, Michael S Ip, Barbara A Blodi, J Michael Jumper, Maria Figueroa, SCORE Study Investigator Group

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00105027 (The Standard Care vs. COrticosteroid for REtinal Vein Occlusion), which is not on this map. Cited by 52 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 7 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00105027 phase3completednot on this map

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema

TypeinterventionalSponsorThe Emmes Company, LLCRan2004 to 2009Enrolled682ConditionsMacular Edema, Cystoid, Retinal Vein OcclusionArmsStandard Care, intravitreal triamcinolone injection
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 7 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2011
    Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Ingrid U ScottDepartment of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Paul C VanVeldhuisen
Neal L Oden
Michael S Ip
Barbara A Blodi
J Michael Jumper
Maria Figueroa
SCORE Study Investigator Group
Emmes (United States) · USUniversity of Wisconsin–Madison · USPenn State Milton S. Hershey Medical Center · USWest Coast Retina · US

Funding

The Intravitreal Corticosteroid for Macular Edema StudyU10EY014351 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI IP, MICHAEL S · 2003 to 2008
$11.5M
SCORE2 Comparative Trial (SCT)U10EY023529 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2013 to 2018
$6.8M
Intravitreal Corticosteroid for Macular EdemaU10EY014404 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2003 to 2008
$3.8M
Intravitreal Corticosteroid for Macular Edema StudyU10EY014352 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI BLODI, BARBARA A · 2003 to 2008
$1.1M
NEI NIH HHS 5U10EY014351NEI NIH HHS 5U10EY014352NEI NIH HHS 5U10EY014404NEI NIH HHS U10 EY014351NEI NIH HHS U10 EY014352NEI NIH HHS U10 EY014404NEI NIH HHS U10 EY023529
6 · The paper itself

Abstract

objectiveTo investigate the relationship between baseline center point retinal thickness measured by optical coherence tomography (OCT) and best-corrected visual acuity in eyes with macular edema associated with retinal vein occlusion and to investigate other factors associated with baseline visual acuity letter score.

designThe Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study includes 2 multicenter, randomized clinical trials: one evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO).

participantsAfter omitting 17 participants with missing or unreliable OCT measurements, analyses proceeded with 665 enrolled SCORE Study participants (665 eyes), including 262 with CRVO and 403 with BRVO.

methodsAt baseline, center point thickness was measured by OCT (Stratus OCT 3 [n=663] and OCT2 [n=2]; Carl Zeiss Meditech, Dublin, CA), and visual acuity was measured by the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) methodology.

main outcome measuresCenter point thickness and best-corrected E-ETDRS visual acuity letter score.

resultsThe correlation coefficient for the association between baseline OCT-measured center point thickness and best-corrected E-ETDRS visual acuity letter score is -0.27 (95% confidence limit: -0.38 to -0.16) for participants in the CRVO trial and -0.28 (95% confidence limit: -0.37 to -0.19) in the BRVO trial. Regression modeling estimated the following decrease in baseline visual acuity letter score for every 100-microm increase in OCT-measured center point thickness: 1.7 letters (P=0.0007) for CRVO and 1.9 letters (P<0.0001) for BRVO. On the basis of multivariate regression models, baseline factors significantly associated (P<0.05, after adjusting for multiple testing) with baseline visual acuity letter score include age and duration of macular edema for CRVO participants and center point thickness and presence of cystoid spaces for BRVO participants.

conclusionsThe correlation between OCT-measured center point thickness and visual acuity letter score is modest. OCT-measured center point thickness represents a useful tool for the detection and monitoring of macular edema in retinal vein occlusion, but it cannot reliably substitute for visual acuity measurements.

Indexed as

AdultAgedAged, 80 and overFemaleGlucocorticoidsHumansInjectionsMacular EdemaMaleMiddle AgedProspective StudiesRetinaRetinal Vein OcclusionTomography, Optical CoherenceTreatment OutcomeTriamcinolone AcetonideGlucocorticoidsTriamcinolone Acetonide

Identifiers

PMID19167078
PMCPMC2851408
OpenAlexW2046518591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.